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value of such observational datasets, relative to the con-
struction or use of RCT study designs. METHODS: A
systematic review of a health economics literature data-
base (HEED) was conducted to explore the use of obser-
vational and RCT data in applied pharmacoeconomic
evaluations in the UK (1990–1999). A comparative anal-
ysis of longitudinal datasets (containing resource use and
outcomes data) developed in the UK (e.g. DIN-LINK,
GPRD) was undertaken with an assessment of the poten-
tial analytical approaches (multivariate techniques, cross-
design synthesis) and methodological and practical con-
siderations. RESULTS: A total of 71 studies were identi-
fied, 59 CEAs only, 6 CUAs only and 6 where both CEAs
and CUAs were conducted. The table presents the type of
data used in these studies for the three core data items of
a pharmacoeconomic evaluation. RCT data represented
the majority source for all three items, in particular for
clinical event and disease outcome data. Observational
data sources were more frequently used to provide re-
source use consequence data. None of the reviewed stud-
ies made use of any existing prospective or retrospective
database. CONCLUSIONS: Regardless of the system of
health care, there is an obvious and universal need for re-
liable data on the effectiveness and costs of clinical inter-
ventions. Observational datasets have implications for
outcomes research conducted in pharmaceutical compa-
nies. There is little literature on the use of observational
data in economic evaluation, and more debate on this
subject is needed. As we gain a better understanding of
the tradeoffs between internal and external validity, it is
predicted that more pharmacoeconomic analyses will in-
creasingly be based on observational data or a combina-
tion of observational and RCT data.
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Data source
Observational RCT
Resource use consequences 21 27
Clinical events 19 37
Disease outcomes 19 33
All 3 sets of core data 9 14
Core data for economic evaluations
Data source
Observational 
& RCT Other
Resource use consequences 3 20
Clinical events 6 9
Disease outcomes 6 13
All 3 sets of core data 1 6
OBJECTIVES: To evaluate the accuracy of claims versus
original prescriptions by calculating the match rate for 7
fields: drug, strength, dosage form, quantity, day’s sup-
ply, daily dose, and date dispensed. Claims accuracy was
also analyzed by therapeutic class for antibiotics, oral hy-
poglycemics, H2 antagonists, antipsychotics, and antide-
pressants. METHODS: Purdue’s Pharmaceutical Eco-
nomics Research Center (PERC) systematically recruited
10 pharmacies from a random list generated by phar-
macy benefits manager PCS Health Systems, Inc. (PCS).
PCS randomly extracted 500 claims submitted by each
pharmacy between 07/01/96 and 06/30/97. Pharmacies
obscured patient information and photocopied the origi-
nal prescriptions. Trained assistants abstracted 5 fields
and calculated day’s supply and daily dose from the di-
rections for use. RESULTS: Six of 10 pharmacies pro-
vided 2,938 photocopies, split approximately evenly
among therapeutic classes. Overall match rates were:
drug (99.9%), strength (97.0%), dosage form (95.5%),
quantity (94.1%), day’s supply (85.2%), daily dose
(83.2%), and date dispensed (65.1%). Applicable mean
percentage differences were: strength (1.32%), daily dose
(2.53%), day’s supply (2.73%), and quantity (6.03%).
The mean difference for date dispensed was 19.3 days.
Match rates were comparable for antidepressants, anti-
psychotics, and H2 antagonists. Antibiotic and oral hy-
poglycemic rates were more variable. CONCLUSIONS:
Claims reliability was excellent for drug, strength, dosage
form, and quantity and good for day’s supply and daily
dose. Antidepressant, antipsychotic, and H2 antagonist
classes had comparable reliability. The reliability of date
dispensed appeared questionable, but the dates recorded
by hand on prescriptions were later than those automati-
cally submitted for claims, suggesting that claims data
may be more accurate than the original prescriptions.
This study found prescription claims to be a reliable data
source for health care research.
PMT3
PREDICTING DRUG SPENDING: UPDATE AND 
EVALUATION OF A REVISED CHRONIC 
DISEASE SCORE
Zhao Z, Boscarino JA, Deverka PA, Epstein RS, Wang Chin J
Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA
When conducting economic analyses using administra-
tive claims, it is important to account for the impact of
comorbidities on healthcare costs. The Chronic Disease
Score (CDS) is a useful risk-adjustment tool for use in
pharmacy claims-based research, however the published
version does not include important new drugs and the
weights were developed from smaller, geographically re-
stricted databases. OBJECTIVES: The purpose of this
study is to: (1) update the number and types of drugs in-
cluded in the CDS (2) develop new weights based on a
large, multi-region pharmacy claims database, and (3)
evaluate the revised CDS in explaining variations in and
predicting drug expenditures. METHODS: Analyses
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were conducted using a leading PBM’s research sample
that contains prescription claims from 3.9 million benefi-
ciaries. Continuously eligibles for 1997 and 1998 were
included. A mapping algorithm was developed to link
each of 27 diseases with their corresponding medication
classes using Standard Therapeutic Class and/or Hierar-
chical Ingredient Code List codes. A weight system was
developed based on relative costs derived using multivari-
ate regression. The second-year drug costs were predicted
based on the first-year demographic and CDS scores. To
assess the accuracy of the prediction models, a random
split-sample method was applied. RESULTS: The revised
CDS was moderately correlated with age (r  0.42) and
had a high year to year correlation of 0.83. It performed
significantly better in explaining variations in and pre-
dicting costs than the demographic model. Adjusted R-
Square for fitting was fourfold higher: 0.65 vs. 0.15 for
log-transformed costs (0.32 vs. 0.06 for actual dollars).
CONCLUSION: The revised CDS is better than demo-
graphics in explaining the variations in prescription drug
costs and predicting the future costs, however further val-
idation work is required. We plan to compare the revised
CDS with the old version to determine the incremental
improvement in predicting both drug and medical cost.
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Markov model is a technique for analyzing events that
repeat or extend over a long period of time. It has been
widely applied to examine the progressions of disease
with well-defined “markers” such as HIV. Most studies
using Markov models suffer from a major limitation of
the “no-memory” assumption. OBJECTIVE: This study
uses HIV cases as an example to demonstrate an alterna-
tive disease progression model: a history- and duration-
dependent transition probability model. METHODS:
This general transition probability model captures pa-
tient’s history of disease states (history-dependency) by
categorizing HIV patients into three types, stable,
progress, and recess, based on whether the patients had
the same disease state, a less severe state, or a more se-
vere state at the previous cycle. For patients with a his-
tory of “stable” disease states, duration in that state was
also included in the model (duration-dependency). Data
from the Multicenter AIDS Cohort Study (MACS) was
used to model the disease progression of HIV patients in
four US cities since 1984. Five disease states were con-
structed using ranges of the CD4/CD8 ratio as the
“marker”. They are: 0.63, 0.42–0.63, 0.31–0.42,
0.31, and death. The cycle length is 6 months. RE-
SULTS: Compared with estimates obtained from either
Markov chain or Markov process models, this general
transition probability model yields better prediction of
life expectancies and allows more flexibility in modeling
the disease progression. CONCLUSIONS: By refining the
disease progression process, our transition probability
model provides a better way to evaluate the effectiveness
as well as cost-effectiveness of treatment alternatives and/
or impacts from alternative health policies.
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OBJECTIVES: Inclusion of patient outcome assessments
in international clinical trials necessitates that cross-cul-
turally valid instrument data be pooled across countries.
Our primary objective is to discuss the development of
patient outcome assessments for use in international tri-
als of patients with upper gastrointestinal disorders.
METHODS: We reviewed the literature and conducted
interviews with subjects and clinical experts prior to de-
veloping symptom and quality of life (QOL) instruments
for patients with upper GI disorders. The instruments
were reviewed by clinical experts and cognitive debrief-
ing of subjects was performed. Following these proce-
dures, forward and backward translation of the instru-
ments into twenty languages was performed. RESULTS:
A total of approximately 120 subjects with gastroesoph-
ageal reflux disease, dyspepsia, or gastroparesis and 12
clinical experts from six countries were interviewed to
determine symptoms and QOL issues they deemed im-
portant. The resulting instruments are the Patient Assess-
ment of Upper GastroIntestinal Disorders-Symptom Se-
verity Index (PAGI-SYM) and Quality of Life Index
(PAGI-QOL). The PAGI-SYM contains 37 items and six
modules representing heartburn, reflux/regurgitation,
nausea/vomiting, abdominal pain/discomfort, bloating/
early satiety/fullness and other symptoms. The PAGI-
QOL has 49 items divided into two sections, QOL and a
general section. The QOL section is comprised of seven
modules: daily activities, concentration/sleep, social ac-
tivities, clothing, diet, relationships, and psychological
state/emotions. The general section contains six items
measuring severity of GI problems, satisfaction, and re-
lief. CONCLUSION: Outcome measures for interna-
tional trials should undergo comprehensive development
and rigorous linguistic validation processes. Initial psy-
chometric testing is currently underway to ensure the in-
struments will behave appropriately across countries.
